The 70-Gene Signature (MammaPrint) as a Guide for the Management of Early Stage Breast Cancer

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	June 2, 2010
Recommendation:	It is recommended that the use of the 70-gene prognostic signature (MammaPrint) does not meet Technology Assessment Criterion 3 through 5 for safety, effectiveness and improvement in health outcomes.
Decision:	Does Not Meet CTAF Criteria
Full Assessment:	Download (PDF)
History:	October 18, 2006: Gene Expression Profiling as a Guide for the Management of Early Stage Breast Cancer

Search Assessments